Drug intelligence / Profile preview

DHNPB-0001

Development stage: Preclinical
Lead developer: Daehan Nupharm

Overview

DHNPB-0001 is a preclinical biologic candidate being developed by Daehan Nupharm for the treatment or prevention of Dengue virus infection. As a biologic agent in the early stages of development, it is part of the company's R&D pipeline focused on infectious diseases. While specific details regarding its molecular structure or precise mechanism of action (such as whether it is a monoclonal antibody, recombinant protein, or vaccine) are not publicly disclosed in detail, it is designed to target the Dengue virus to mitigate infection or disease progression.

Beyond the preview

Go deeper on DHNPB-0001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DHNPB-0001.

Explore the full profile